Immunogenetic Differences between Caucasian Women with & without Silicone Implants in whom Myositis Develops
Bethesda, MD: NIH Clinical Center
Supplementary Table. Comparisons of clinical signs and symptoms, myositis autoantibodies and local complications associated with the use of silicone implants between MASI patients and matched IIM or SIC study groups
Clinical Signs /
Symptoms
MASI,
n=26
n (%)
IIM,
n=52
n (%)
Fatigue
26 (100)
14 (26.9)
Weight Loss
11 (42.3)
19 (36.5)
Fatigue
26 (100)
47 (90.4)
Raynaud’s Sign
11 (42.3)
25 (48.1)
Sjogren’s Syndrome
15 (57.7)
19 (36.5)
Proximal Weakness
26 (100)
46 (88.5)
Distal Weakness
12 (46.2)
19 (36.5)
Asymmetric Weakness
5 (19.2)
14 (26.9)
Muscle Cramps
9 (34.6)
21 (40.4)
Arthralgias
19 (73.1)
24 (46.2)
Arthritis
14 (53.8)
19 (36.5)
Falling
5 (19.2)
13 (25.0)
Muscle Atrophy
6 (23.1)
19 (36.5)
Contractures
3 (11.5)
4 (7.7)
Carpel Tunnel
4 (15.4)
10 (19.2)
Dyspnea (EX)
16 (61.5)
20 (38.5)
Dyspnea (RE)
7 (26.9)
9 (17.3)
O2 Use
4 (15.4)
6 (11.2)
Changes Pulmonary Funct.
7 (26.9)
9 (17.3)
Interstitial Lung Disease
8 (30.8)
11 (21.2)
Cough
5 (19.2)
11 (21.2)
Chest Pain
2 (7.7)
5 (9.6)
Palpitation
5 (19.2)
15 (28.8)
Edema
13 (50.0)
16 (30.8)
Syncope
0 (0)
2 (3.8)
Dysphagia
12 (46.2)
24 (46.2)
Regurgitation
5 (19.2)
7 (13.5)
Diarrhea
2 (7.7)
6 (11.2)
Heliotrope Rash
9 (34.6)
19 (36.5)
V Sign Rash
5 (19.2)
10 (19.2)
Shawl Sign Rash
3 (11.5)
12 (23.1)
Gottron’s Papules
10 (38.5)
17 (32.7)
Other Rashes
4 (15.4)
17 (32.7)
Mechanic’s Hands
4 (15.4)
7 (13.5)
Nailbed Changes
4 (15.4)
6 (11.2)
Cuticular Overgrowth
3 (11.5)
6 (11.2)
Lymphadenopathy
3 (11.5)
1 (1.9)
Myositis-Specific
Autoantibodies
(MSA)
MASI,
n=26
n (%)
IIM,
n=51**
n (%)
MSA
8 (30.8)
22 (43.1)
Synthetase
5 (19.2)
18 (35.3)
Jo-1
3 (11.5)
14 (27.5)
THR
1 (3.8)
3 (5.9)
ILE
1 (3.8)
1 (2.0)
Mi-2
2 (7.7)
3 (5.9)
SRP
1 (3.8)
1 (2.0)
Myositis-Associated
Autoantibodies
(MAA)
MASI,
n=26
n (%)
IIM,
n=51**
n (%)
MAA
6 (23.1)
16 (31.4)
KU
0 (0)
0 (0)
LA
0 (0)
5 (9.8)
RO
3 (11.5)
6 (11.8)
PM/Scl
0 (0)
1 (2.0)
SM
0 (0)
2 (3.9)
RNP
3 (11.5)
2 (3.9)
Local
Complications
MASI,
n=26
n (%)
SIC,
n=52**
n (%)
Contracture
12 (46.2)
29 (55.8)
Rupture
8 (30.8)
18 (34.6)
Pain
6 (23.1)
11 (21.2)
Infection
3 (11.5)
5 (9.6)
Bleeding
0 (0)
7 (13.5)
Lumps/Asymmetry
7 (26.9)
9 (17.3)
LNE
4 (15.4)
8 (15.4)
Explants
17 (65.4)
28 (53.8)
* Abbreviations per manuscript Table 1 and Jo-1, anti-histidyl tRNA synthetase; THR, anti-threonyl tRNA synthetase; ILE, anti-isoleucyl tRNA synthetase; Mi-2, anti-Mi-2; SRP, anti-signal recognition particle; LNE, lymph node enlargement. There were no significant differences (after correction for multiple comparisons) regarding these data among the groups.
**Serum was unavailable for 1 of 52 IIM patients.
|